Recurrent seizure at 6 months · children with febrile seizures
Continuous phenobarbital probably leads to lower recurrent seizure at 6 months compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Recurrent seizure at 12 months · children with febrile seizures
Continuous phenobarbital may leads to lower recurrent seizure at 12 months compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Effects on adherence (behavioural interventions) · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
Effects on adherence (educational interventions) · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
Effects on adherence (mixed interventions) · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
Seizure frequency and/or seizure severity Assessed by National Hospital Seizure Severity Scale (NHS3), seizure diary and self‐reporting · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
Self‐efficacy · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
Quality of life · adults and children with epilepsy
1 finding from 1 review
Intervention not reported
≥ 50% reduction in seizure frequency 2‐month · children with SMEI
The intervention probably leads to higher ≥ 50% reduction in seizure frequency 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Seizure freedom 2‐month · children with SMEI
The intervention probably leads to higher seizure freedom 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of dropouts 2‐month · children with SMEI
The intervention showed no clear difference in proportion of dropouts 2‐month (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse effects · children with SMEI
The intervention may leads to higher adverse effects (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who are seizure free between 4‐40 weeks · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who are seizure free between 4‐40 weeks (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with an adverse event · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients with an adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Changes in cognitive function · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who are seizure free at 28 weeks · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who are seizure free at 28 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients with an adverse event: · Patients between five and 15 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients with a particular or serious adverse event: 1. Somnolence 2. Rash · Patients between five and 15 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Changes in cognitive function testing from baseline (28 weeks trial period) · Patients between five and 15 years old with a diagnosis of BECTS
1 finding from 1 review
Intervention not reported
Proportion of patients who are seizure free at 3 months · Patients between three and 10 years old with a diagnosis of BECTS
The intervention probably leads to higher proportion of patients who are seizure free at 3 months (moderate certainty).
1 finding from 1 review